MUFG Americas’s Aegerion Pharmaceuticals AEGR Stock Holding History

MUFG Americas’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-32	Closed	–	–	1289
2015 Q4	$0	Buy	+32	New	+$385	﹤0.01%	1292

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

MUFG Americas's AEGR Position: Q1 2016 in Review

MUFG Americas sold out of Aegerion Pharmaceuticals (AEGR) in Q1 2016, closing a stake of 32 shares.

MUFG Americas first reported a position in AEGR in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 101 funds tracked by Wall St. Rank hold AEGR as of Q1 2016.

MUFG Americas reported no remaining Aegerion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
MUFG Americas sold 32 Aegerion Pharmaceuticals shares in Q1 2016.
MUFG Americas first reported a position in Aegerion Pharmaceuticals in Q4 2015 and held it in 1 quarter.
MUFG Americas's Aegerion Pharmaceuticals position peaked at $0 in Q4 2015.
101 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q1 2016.

Based on MUFG Americas's 13F filing for Q1 2016, filed 11 May 2016.